CheckpointPx, our AI powered model, analyzes CT scans to predict response to ICI treatment for lung cancer. It goes beyond the standard, but limited, PD-L1 biomarker by identifying potential responders who would be missed otherwise, particularly, those with low or negative PD-L1 expression. This could significantly improve patient selection for clinical trials.
Read the full article HERE
Publication
CheckpointPx, an interpretable radiology AI tool, predicts immune checkpoint blockade benefit independent of PDL1 status in non-small cell lung cancer (NSCLC): A multi-institutional validation study
AACR Annual Meeting 2024,
March 22, 2024
